IL105498A - Pharmaceutical composition containing ribonucleotide polymerase - Google Patents

Pharmaceutical composition containing ribonucleotide polymerase

Info

Publication number: IL105498A
Authority: IL; Israel
Prior art keywords: polymerase; composition; rna polymerase; ribonucleotide; days
Prior art date: 1992-04-22

Application number

IL105498A

Other languages

English (en)

Other versions

IL105498A0 (en

Original Assignee

Molecular Rx

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-22

Filing date

1993-04-22

Publication date

1998-02-08

1993-04-22 Application filed by Molecular Rx filed Critical Molecular Rx

1993-08-18 Publication of IL105498A0 publication Critical patent/IL105498A0/xx

1998-02-08 Publication of IL105498A publication Critical patent/IL105498A/en

Links

108010018600 ribonucleotide polymerase Proteins 0.000 title claims abstract description 44
239000008194 pharmaceutical composition Substances 0.000 title description 4
239000000203 mixture Substances 0.000 claims abstract description 32
208000026278 immune system disease Diseases 0.000 claims abstract description 9
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 50
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 50
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 14
239000011780 sodium chloride Substances 0.000 claims description 14
102100034343 Integrase Human genes 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
235000011187 glycerol Nutrition 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
102000005348 Neuraminidase Human genes 0.000 claims description 3
108010006232 Neuraminidase Proteins 0.000 claims description 3
229960001340 histamine Drugs 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 35
238000011282 treatment Methods 0.000 abstract description 30
241001465754 Metazoa Species 0.000 abstract description 16
208000035475 disorder Diseases 0.000 abstract description 13
230000004064 dysfunction Effects 0.000 abstract description 9
230000001900 immune effect Effects 0.000 abstract description 8
238000000034 method Methods 0.000 abstract description 4
241000283073 Equus caballus Species 0.000 description 26
241000699670 Mus sp. Species 0.000 description 26
206010003246 arthritis Diseases 0.000 description 24
208000024891 symptom Diseases 0.000 description 24
201000010099 disease Diseases 0.000 description 22
230000000694 effects Effects 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 15
102000008186 Collagen Human genes 0.000 description 12
108010035532 Collagen Proteins 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
229920001436 collagen Polymers 0.000 description 12
201000000596 systemic lupus erythematosus Diseases 0.000 description 11
238000007920 subcutaneous administration Methods 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
230000004044 response Effects 0.000 description 9
230000028993 immune response Effects 0.000 description 8
210000001503 joint Anatomy 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
239000000427 antigen Substances 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
210000001744 T-lymphocyte Anatomy 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000002917 arthritic effect Effects 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000010254 subcutaneous injection Methods 0.000 description 6
239000007929 subcutaneous injection Substances 0.000 description 6
230000008961 swelling Effects 0.000 description 6
102000000503 Collagen Type II Human genes 0.000 description 5
108010041390 Collagen Type II Proteins 0.000 description 5
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 5
241001537210 Perna Species 0.000 description 5
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 5
210000003414 extremity Anatomy 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
239000012528 membrane Substances 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
238000002965 ELISA Methods 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
206010071578 autoimmune retinopathy Diseases 0.000 description 4
108700003601 dimethylglycine Proteins 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
206010073767 Developmental hip dysplasia Diseases 0.000 description 3
208000007446 Hip Dislocation Diseases 0.000 description 3
208000029462 Immunodeficiency disease Diseases 0.000 description 3
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000036783 anaphylactic response Effects 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000005784 autoimmunity Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000004124 hock Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000000266 injurious effect Effects 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
230000008685 targeting Effects 0.000 description 3
206010043778 thyroiditis Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
206010002198 Anaphylactic reaction Diseases 0.000 description 2
208000033399 Anaphylactic responses Diseases 0.000 description 2
208000006820 Arthralgia Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
241000701832 Enterobacteria phage T3 Species 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241001646716 Escherichia coli K-12 Species 0.000 description 2
206010015967 Eye swelling Diseases 0.000 description 2
206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
208000024869 Goodpasture syndrome Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010036030 Polyarthritis Diseases 0.000 description 2
208000021386 Sjogren Syndrome Diseases 0.000 description 2
241000191940 Staphylococcus Species 0.000 description 2
201000009594 Systemic Scleroderma Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000003172 anti-dna Effects 0.000 description 2
230000003460 anti-nuclear Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
230000009266 disease activity Effects 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
208000007475 hemolytic anemia Diseases 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
208000018937 joint inflammation Diseases 0.000 description 2
210000000629 knee joint Anatomy 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000005951 type IV hypersensitivity Effects 0.000 description 2
208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
201000003066 Diffuse Scleroderma Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
208000005777 Lupus Nephritis Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
208000009793 Milk Hypersensitivity Diseases 0.000 description 1
201000010859 Milk allergy Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
-1 Nucleoside triphosphate Chemical class 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
208000006311 Pyoderma Diseases 0.000 description 1
108010013845 RNA Polymerase I Proteins 0.000 description 1
102000017143 RNA Polymerase I Human genes 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
229940083741 banamine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000023402 cell communication Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000028659 discharge Diseases 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
210000001513 elbow Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
208000028327 extreme fatigue Diseases 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
208000001031 fetal erythroblastosis Diseases 0.000 description 1
239000012530 fluid Substances 0.000 description 1
MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
201000005298 gastrointestinal allergy Diseases 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000001624 hip Anatomy 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
230000009390 immune abnormality Effects 0.000 description 1
230000008088 immune pathway Effects 0.000 description 1
230000003832 immune regulation Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
229960005287 lincomycin Drugs 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
201000005737 orchitis Diseases 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
206010040400 serum sickness Diseases 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000006557 surface reaction Methods 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07006—DNA-directed RNA polymerase (2.7.7.6)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

IL105498A 1992-04-22 1993-04-22 Pharmaceutical composition containing ribonucleotide polymerase IL105498A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87196892A	1992-04-22	1992-04-22
US4661193A	1993-04-19	1993-04-19

Publications (2)

Publication Number	Publication Date
IL105498A0 IL105498A0 (en)	1993-08-18
IL105498A true IL105498A (en)	1998-02-08

Family

ID=26724124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL105498A IL105498A (en)	1992-04-22	1993-04-22	Pharmaceutical composition containing ribonucleotide polymerase

Country Status (8)

Country	Link
US (2)	US5804188A (de)
EP (1)	EP0642333B1 (de)
JP (1)	JP3468519B2 (de)
CN (1)	CN1091316A (de)
AT (1)	ATE167628T1 (de)
DE (1)	DE69319341T2 (de)
IL (1)	IL105498A (de)
WO (1)	WO1993020803A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5961969A (en) *	1996-05-14	1999-10-05	Maxim Pharmaceuticals, Inc.	Stable circulating histamine levels
US6071942A (en) *	1996-05-14	2000-06-06	Maxim Pharmaceuticals, Inc.	Elevation of circulating blood histamine levels
US20060024301A1 (en) *	1997-02-25	2006-02-02	Corixa Corporation	Prostate-specific polypeptides and fusion polypeptides thereof
US20030185830A1 (en) *	1997-02-25	2003-10-02	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) *	1997-02-25	2006-11-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US7048931B1 (en) *	2000-11-09	2006-05-23	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
MX2007013850A (es) *	2005-05-02	2008-04-09	4Life Patents Llc	Preparaciones de factor de transferencia y metodos asociados.
US9028882B2 (en)	2005-05-02	2015-05-12	4Life Patents, Llc	Nutraceutical gels

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4294818A (en) *	1979-07-30	1981-10-13	University Patents, Inc.	Methods and materials for detection of multiple sclerosis
US4582793A (en) *	1982-10-29	1986-04-15	Research Corporation	Anti-RNA polymerase I antibody test for the diagnosis of rheumatological diseases
US4751181A (en) *	1984-12-31	1988-06-14	Duke University	Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US5077211A (en) *	1988-07-06	1991-12-31	Applied Genetics, Inc.	Purification and administration of dna repair enzymes
US5116615A (en) *	1989-01-27	1992-05-26	Immunolytics, Inc.	Method for treating benign prostatic hypertrophy

1993
- 1993-04-21 JP JP51869293A patent/JP3468519B2/ja not_active Expired - Fee Related
- 1993-04-21 DE DE69319341T patent/DE69319341T2/de not_active Expired - Lifetime
- 1993-04-21 EP EP93910701A patent/EP0642333B1/de not_active Expired - Lifetime
- 1993-04-21 AT AT93910701T patent/ATE167628T1/de not_active IP Right Cessation
- 1993-04-21 WO PCT/US1993/003757 patent/WO1993020803A1/en not_active Ceased
- 1993-04-22 IL IL105498A patent/IL105498A/en not_active IP Right Cessation
- 1993-04-22 CN CN93105903A patent/CN1091316A/zh active Pending
1995
- 1995-03-29 US US08/413,921 patent/US5804188A/en not_active Expired - Lifetime
- 1995-06-07 US US08/478,223 patent/US5846532A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5846532A (en)	1998-12-08
WO1993020803A1 (en)	1993-10-28
JP3468519B2 (ja)	2003-11-17
EP0642333A4 (de)	1994-12-19
EP0642333B1 (de)	1998-06-24
DE69319341T2 (de)	1999-02-11
IL105498A0 (en)	1993-08-18
US5804188A (en)	1998-09-08
AU676161B2 (en)	1997-03-06
JPH07505893A (ja)	1995-06-29
CN1091316A (zh)	1994-08-31
EP0642333A1 (de)	1995-03-15
ATE167628T1 (de)	1998-07-15
AU4110493A (en)	1993-11-18
DE69319341D1 (de)	1998-07-30

Legal Events

Date	Code	Title
1998-07-15	FF	Patent granted
1998-12-27	KB	Patent renewed
1999-10-28	KB	Patent renewed
2003-07-06	KB	Patent renewed
2007-07-06	KB	Patent renewed
2011-12-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
Sanberg	1980	Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors
US4734279A (en)	1988-03-29	Combination of immunoglobulins with therapeutic agents
Barak et al.	2002	Involvement of brain cytokines in the neurobehavioral disturbances induced by HIV-1 glycoprotein120
US5846532A (en)	1998-12-08	Method and composition for the treatment of disorders involving immunological dysfunction
AU2026201137A1 (en)	2026-03-05	Compositions and methods for promoting islet viability and enhancing insulin secretion
EP0977581B1 (de)	2002-07-17	Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
US9555070B2 (en)	2017-01-31	Pan-antiviral peptides for protein kinase inhibition
EP3345614A1 (de)	2018-07-11	Zusammensetzung mit alkalinphosphatase zur verwendung bei der behandlung von arthritiden
EP0571597A1 (de)	1993-12-01	Verfahren zur behandlung von akuten und chronischen schmerzhaften arthropathien beim menschen und bei anderen säugern
EP0554887A1 (de)	1993-08-11	Verwendung eines Säugetiere-Leberextraktes zur Herstellung eines Arzneimittels gegen senile und presenile Demenz
Gorin et al.	1990	Stiff‐man syndrome: a GABAergic autoimmune disorder with autoantigenic heterogeneity
CA2133995C (en)	2007-07-24	Method and composition for the treatment of disorders involving immunological dysfunction
AU676161C (en)	1997-12-11	Method and composition for the treatment of disorders involving immunological dysfunction
Goss	1961	Metabolic antagonists and prolonged survival of scale homografts in Fundulus heteroclitus
Skurkovich et al.	1994	A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic
JPH07507061A (ja)	1995-08-03	多発性硬化症を含めた炎症の治療におけるペプチドｔ及びその関連ペプチド類
French	1952	The pyrogenic effect of the influenza-mumps group of viruses in the laboratory rabbit.
US7807635B1 (en)	2010-10-05	Pan-antiviral peptides for protein kinase inhibition
Roberton et al.	1988	Failure of intraventricular gammaglobulin and alpha interferon for persistent encephalitis in congenital hypogammaglobulinaemia.
US5409901A (en)	1995-04-25	Therapeutic compositions comprising nucleoproteins as the active agents, and methods of producing and using such compositions
Carey et al.	1944	Sudden destruction of motor end plates by lactic acid
Kunikata et al.	2002	Lumin, a cyanine dye, enhances interleukin 12-dependent interferon gamma production by lipopolysaccharide-stimulated mouse splenocytes
Hashim	1980	Failure of myelin basic protein to prevent or suppress experimental allergic encephalomyelitis in guinea pigs
US20250205320A1 (en)	2025-06-26	Methods of treating polycystic kidney disease
SU1022713A1 (ru)	1983-06-15	Способ лечени больных торпидно текущим псориазом